Oncotarget

Research Papers:

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer

Mitsukuni Suenaga _, Tetsuo Mashima, Naomi Kawata, Takeru Wakatsuki, Yuki Horiike, Satoshi Matsusaka, Shingo Dan, Eiji Shinozaki, Hiroyuki Seimiya, Nobuyuki Mizunuma, Kensei Yamaguchi and Toshiharu Yamaguchi

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:34811-34823. https://doi.org/10.18632/oncotarget.9187

Metrics: PDF 1494 views  |   HTML 1603 views  |   ?  


Abstract

Mitsukuni Suenaga1, Tetsuo Mashima2, Naomi Kawata1,2, Takeru Wakatsuki1, Yuki Horiike1, Satoshi Matsusaka1, Shingo Dan3, Eiji Shinozaki1, Hiroyuki Seimiya2, Nobuyuki Mizunuma1, Kensei Yamaguchi1, Toshiharu Yamaguchi4

1Department of Gastroenterological and Chemotherapy Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo 135–8550, Japan

2Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Koto-ku, Tokyo 135–8550, Japan

3Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Koto-ku, Tokyo 135–8550, Japan

4Department of Gastroenterological and Surgery Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo 135–8550, Japan

Correspondence to:

Mitsukuni Suenaga, email: m.suenaga@jfcr.or.jp

Keywords: regorafenib, metastatic colorectal cancer, VEGF-A, CCL5, prognostic marker

Received: December 27, 2015     Accepted: April 16, 2016     Published: May 05, 2016

ABSTRACT

Regorafenib is an oral multi-kinase inhibitor used as salvage therapy for metastatic colorectal cancer (mCRC). We tested whether serum cytokine levels are associated with clinical outcome in the mCRC patients receiving regorafenib. Serum samples were collected before treatment start, day 21, and progressive disease, and eleven angiogenic and inflammatory cytokine serum levels were examined. Fifty-four patients of a total of 62 enrolled patients were eligible for the analyses. The chemokine ligand 5 (CCL5) levels ≤ cut-off value (59959 pg/ml) at baseline was associated with relative tumor shrinkage (P = 0.021), better progression-free survival (PFS) (P = 0.036) and overall survival (OS) (P = 0.019). Vascular endothelial growth factor A (VEGF-A) levels showing a decrease on day 21 were significantly associated with a better PFS (P = 0.021). CCL5 levels ≤ cut-off was associated with any grade hand-foot skin reaction (HFSR) (P = 0.025) and thrombocytopenia (P = 0.013). Low chemokine ligand 2 levels at baseline were associated with grade 2 ≤ HFSR. High angiopoietin-2 and basic fibroblast growth factor (bFGF) levels at baseline were associated with grade 3 ≤ total bilirubin increase and transaminases increase, respectively. Low bFGF levels at baseline were associated with grade 3 ≤ hypertension. No correlation with severe events was observed. Baseline serum CCL5 levels and decrease of the serum VEGF-A levels may serve as potential predictive markers for survival or treatment-specific toxicities in mCRC patients receiving regorafenib.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9187